Gordon Stein, CFO of CleanTech Lithium, explains why CTL acquired the 23 Laguna Verde licenses. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
AndytheMKDon - thank you, that’s what I was driving at. Given the situation there’ll be no delaying the development of what could be a massively important addition to the treatment options available.
With a potential lockdown likely to be announced later today and a vaccine looking a long way off, if at all, then the focus on antivirals and autoimmune products becomes more pressing than ever. Our share price could move very quickly as the government scramble for a solution and the news media start to open their gaze towards therapeutics rather than just vaccines. Gla. Andy. :+)
No probs. 10 million shares............very very nice!
Good man Mayhem, brothers in arms
Thanks cobaltblue, well spotted, my average is around 1p a share .
Yes I am in a similar position, having been in sar for 10 yrs ish. I have accumulated 10 million shares and have been an avid reader of the wise people on this board. My analysis is the share price will increase on the various milestones, personal view is we could achieve 18 to 26p in the short term. Looking at the bigger picture assuming all goes to plan then my assessment is £1 is very achievable and to Thoth’s many points many multiples are feasible.
"I have got my Average down to around £1 a share "
fearg, typo?!
While it appears that SAR has made tremendous gains since February, it is not the whole story as the valuation was up to 1.5 around 2 years ago when I started to take a renewed interest because of SRA 737 . Personally I found it very difficult to invest in February at.23 pence as my confidence was low despite the posters on here who could recognise the value. To be honest I had been badly burned by other shares like Tullow and Orm. it was only when the share price approached .7p that I regained the confidence to reinvest. The posters who were making the case for SAR are largely the same posters who keep analysing and pricing the further development of SAR. I am now very happy with a share holding of just over 10 million shares and, believe me, I read the posters on here every day that I can. This investment is substantial for me though obviously not at the level of a number on here who fully appreciated what SAR could achieve at it's lowest point. this board has become essential reading for me and, I suspect, many on here in keeping abreast of and a good read to date. I like to give my tuppence halfpenny's worth on occasions also. I have never sold any SAR shares and I think the potential is there to replicate the last nine months. I have got my Average down to around £1 a share so for me I have serious skins in the game. Good licence deals for 1801 and 1802, which you are predicting Fedec, would de-risk this share price. Dilly must **** or get off the pot and good news from China on FLT could also prove very significant and would also de-risk. Not a scenario that would have me trading any of my shares at this stage. Tim continues to indicate that he is in negotiations, hopefully an auction situation. A buy out by a major pharma would transform the lives of many on here. A split deal of say 25p with a continuing share income deal would be attractive. A total buy out from a major Pharma would also be transform the lives of many on here. There you have it, my latest confession.
In response to a written question regarding the timelines for the development of SDC1801 in Covid, Tim/John state:
"This would follow the normal pattern for any development programme, albeit with the opportunity to compress timeframes depending on levels of funding and support....... "Given the pressing need for new therapies to treat Covid-19, it may be that there will be accelerated paths to approval"
It must be safe to assume that timelines will be compressed as much as clinically appropriate so the question is whether the 6 months grant funding referred to in the RNS is based on a compressed timeline and if not, by how much could the timeline be shortened?
Q18: Can you describe the process of progressing SDC-1801 in COVID trials?
This would follow the normal pattern for any development programme, albeit with the opportunity to compress timeframes depending on levels of funding and support.
The grant funding, if our application is successful, would cover the initial lab and other preclinical studies that aim to demonstrate that our molecules are effective against the overactive immune response seen in Covid-19 (and other viral respiratory infections). If and when that is achieved – and also considering the safety/tox and other data from the formal preclinical studies - we will look to incorporate the successful molecules into the clinical trial programme being run by UKRI as quickly as possible.
Phase 1 clinical studies would be needed to demonstrate safety in healthy volunteers, before moving on to look at efficacy in later stage studies.
Given the pressing need for new therapies to treat Covid-19, it may be that there will be accelerated paths to approval.